ArticleMolecular neurobiology2026
A Dose-Response Study on Human FGF21 to Inhibit Necrosis, Spectrin Breakdown, and to Increase Intracellular Cold Shock Proteins in Cultured Cortical Neurons Subjected to Oxygen-Glucose Deprivation Injury.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cold-stress hormone fibroblast growth factor 21 (FGF21) induces a broad spectrum of neuroprotective effects, including a blunting effect on α-II-spectrin breakdown product 145 (SBDP145) levels in models of hypoxia-ischemia (HI). Here, we studied the impact of FGF21 dosing on cell survival and on SBDP145 levels in normothermic male/female cortical neurons in an oxygen-glucose deprivation (OGD) injury model of necrosis. We also explored the impact of FGF21 dosing on cold-shock proteins RNA-binding motif 3 (RBM3) and cold-induced RNA-binding protein (CIRBP) in the OGD injury model. FGF21 concentrations ≥ 100 ng/mL attenuated postinsult increases in SBDP145 levels but had no effect on acute (24 h) or delayed (48-72 h) neuronal survival at normothermia. Further, FGF21 treatment at the highest dose tested (10 µg/mL) induced a sparing effect on postinsult RBM3 levels. This prompted follow-up studies to test if combination therapy with FGF21 and therapeutic hypothermia (TH)-induced synergistic benefits on cell survival. Only intraischemic TH increased 24-h cell survival in our model. FGF21 had no effect on cell survival when combined with intraischemic or posttreatment TH. Finally, we verified that necrosis was the primary mechanism of cell death induced by OGD injury in our model. Pretreatment with calpain inhibitors decreased markers of necrosis, but increased markers of autophagy/apoptosis, and had no effect on 24-h cell survival. In contrast, pretreatment with NMDA receptor antagonist MK801 robustly increased 24-h cell survival. In summary, FGF21 posttreatment (≥ 100 ng/mL) primarily alleviated α-II-spectrin disruption in an OGD model of excitotoxicity-induced necrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.